最新单价 XBB.1.5 COVID-19 疫苗对韩国症状性 SARS-CoV-2 感染、住院和接受氧气治疗的有效性估计 - 2023 年 10 月 26 日至 12 月 31 日。

IF 4.8 2区医学 Q1 INFECTIOUS DISEASES

International Journal of Infectious Diseases Pub Date : 2024-09-20 DOI:10.1016/j.ijid.2024.107249

Jung Ah Lee , Heeseon Jang , Sang Min Ahn , Jae Eun Seong , Young Keun Kim , Yujin Sohn , Sook In Jung , Hye Won Jeong , Shin-Woo Kim , Jin-Soo Lee , Ji-Hyeon Baek , Se Ju Lee , Geun-Yong Kwon , Jeeyeon Shin , Hangjin Jeong , Changsoo Kim , Jun Yong Choi

{"title":"最新单价 XBB.1.5 COVID-19 疫苗对韩国症状性 SARS-CoV-2 感染、住院和接受氧气治疗的有效性估计 - 2023 年 10 月 26 日至 12 月 31 日。","authors":"Jung Ah Lee , Heeseon Jang , Sang Min Ahn , Jae Eun Seong , Young Keun Kim , Yujin Sohn , Sook In Jung , Hye Won Jeong , Shin-Woo Kim , Jin-Soo Lee , Ji-Hyeon Baek , Se Ju Lee , Geun-Yong Kwon , Jeeyeon Shin , Hangjin Jeong , Changsoo Kim , Jun Yong Choi","doi":"10.1016/j.ijid.2024.107249","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>We evaluated the vaccine effectiveness of monovalent XBB.1.5 vaccine against symptomatic COVID-19 infection, hospitalization, and the need for oxygen therapy in South Korea.</div></div><div><h3>Design</h3><div>This study employed a test-negative case-control design. COVID-19 test results in symptomatic subjects from six university hospitals across South Korea were collected (October 26–December 31, 2023). The adjusted absolute and relative vaccine effectiveness were assessed.</div></div><div><h3>Results</h3><div>In total, 5516 subjects were enrolled: 4,824 were unvaccinated with XBB.1.5, and 692 were vaccinated with XBB.1.5 COVID-19 mRNA vaccines. The absolute vaccine effectiveness when comparing the odds between XBB.1.5 vaccination and no vaccination against symptomatic COVID-19 infection, hospitalization, and oxygen therapy was 65.2% (95% CI, 36.1-81.0), 77.3% (95% CI, 51.1-89.5), and 85.3% (95% CI, 57.8-94.9), respectively. The relative vaccine effectiveness when comparing the odds between XBB.1.5 vaccination and no XBB.1.5 vaccination against symptomatic COVID-19 infection, hospitalization, and oxygen therapy was 57.7% (95% CI, 34.7-72.6), 64.3% (95% CI, 35.9-80.2), and 65.5% (95% CI, 27.0-83.7), respectively.</div></div><div><h3>Conclusion</h3><div>The short-term effectiveness of the XBB.1.5 vaccine against symptomatic COVID-19 infection, hospitalization, and receipt of oxygen therapy in South Korea was significant. Long-term vaccine effectiveness warrants evaluation, and these assessments should be conducted regularly.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"148 ","pages":"Article 107249"},"PeriodicalIF":4.8000,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Estimates of vaccine effectiveness of the updated monovalent XBB.1.5 COVID-19 vaccine against symptomatic SARS-CoV-2 infection, hospitalization, and receipt of oxygen therapy in South Korea - October 26 to December 31, 2023\",\"authors\":\"Jung Ah Lee , Heeseon Jang , Sang Min Ahn , Jae Eun Seong , Young Keun Kim , Yujin Sohn , Sook In Jung , Hye Won Jeong , Shin-Woo Kim , Jin-Soo Lee , Ji-Hyeon Baek , Se Ju Lee , Geun-Yong Kwon , Jeeyeon Shin , Hangjin Jeong , Changsoo Kim , Jun Yong Choi\",\"doi\":\"10.1016/j.ijid.2024.107249\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><div>We evaluated the vaccine effectiveness of monovalent XBB.1.5 vaccine against symptomatic COVID-19 infection, hospitalization, and the need for oxygen therapy in South Korea.</div></div><div><h3>Design</h3><div>This study employed a test-negative case-control design. COVID-19 test results in symptomatic subjects from six university hospitals across South Korea were collected (October 26–December 31, 2023). The adjusted absolute and relative vaccine effectiveness were assessed.</div></div><div><h3>Results</h3><div>In total, 5516 subjects were enrolled: 4,824 were unvaccinated with XBB.1.5, and 692 were vaccinated with XBB.1.5 COVID-19 mRNA vaccines. The absolute vaccine effectiveness when comparing the odds between XBB.1.5 vaccination and no vaccination against symptomatic COVID-19 infection, hospitalization, and oxygen therapy was 65.2% (95% CI, 36.1-81.0), 77.3% (95% CI, 51.1-89.5), and 85.3% (95% CI, 57.8-94.9), respectively. The relative vaccine effectiveness when comparing the odds between XBB.1.5 vaccination and no XBB.1.5 vaccination against symptomatic COVID-19 infection, hospitalization, and oxygen therapy was 57.7% (95% CI, 34.7-72.6), 64.3% (95% CI, 35.9-80.2), and 65.5% (95% CI, 27.0-83.7), respectively.</div></div><div><h3>Conclusion</h3><div>The short-term effectiveness of the XBB.1.5 vaccine against symptomatic COVID-19 infection, hospitalization, and receipt of oxygen therapy in South Korea was significant. Long-term vaccine effectiveness warrants evaluation, and these assessments should be conducted regularly.</div></div>\",\"PeriodicalId\":14006,\"journal\":{\"name\":\"International Journal of Infectious Diseases\",\"volume\":\"148 \",\"pages\":\"Article 107249\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2024-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1201971224003205\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1201971224003205","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

目的我们评估了单价XBB.1.5疫苗对韩国无症状COVID-19感染、住院和氧疗需求的预防效果：本研究采用试验阴性病例对照设计。收集了韩国六所大学医院有症状受试者的 COVID-19 检测结果（2023 年 10 月 26 日至 12 月 31 日）。结果：结果：共有 5,516 名受试者参与了研究：结果：共招募了 5516 名受试者：4824 人未接种 XBB.1.5 疫苗，692 人接种了 XBB.1.5 COVID-19 mRNA 疫苗。比较接种 XBB.1.5 疫苗和未接种疫苗对无症状 COVID-19 感染、住院和氧疗的几率，疫苗的绝对有效性分别为 65.2%（95% CI，36.1-81.0）、77.3%（95% CI，51.1-89.5）和 85.3%（95% CI，57.8-94.9）。比较接种XBB.1.5疫苗和不接种XBB.1.5疫苗对无症状COVID-19感染、住院和氧疗的几率，疫苗的相对有效性分别为57.7%（95% CI，34.7-72.6）、64.3%（95% CI，35.9-80.2）和65.5%（95% CI，27.0-83.7）：在韩国，XBB.1.5疫苗对无症状COVID-19感染、住院和接受氧疗的短期效果显著。疫苗的长期有效性值得评估，这些评估应定期进行。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Estimates of vaccine effectiveness of the updated monovalent XBB.1.5 COVID-19 vaccine against symptomatic SARS-CoV-2 infection, hospitalization, and receipt of oxygen therapy in South Korea - October 26 to December 31, 2023

Objectives

We evaluated the vaccine effectiveness of monovalent XBB.1.5 vaccine against symptomatic COVID-19 infection, hospitalization, and the need for oxygen therapy in South Korea.

Design

This study employed a test-negative case-control design. COVID-19 test results in symptomatic subjects from six university hospitals across South Korea were collected (October 26–December 31, 2023). The adjusted absolute and relative vaccine effectiveness were assessed.

Results

In total, 5516 subjects were enrolled: 4,824 were unvaccinated with XBB.1.5, and 692 were vaccinated with XBB.1.5 COVID-19 mRNA vaccines. The absolute vaccine effectiveness when comparing the odds between XBB.1.5 vaccination and no vaccination against symptomatic COVID-19 infection, hospitalization, and oxygen therapy was 65.2% (95% CI, 36.1-81.0), 77.3% (95% CI, 51.1-89.5), and 85.3% (95% CI, 57.8-94.9), respectively. The relative vaccine effectiveness when comparing the odds between XBB.1.5 vaccination and no XBB.1.5 vaccination against symptomatic COVID-19 infection, hospitalization, and oxygen therapy was 57.7% (95% CI, 34.7-72.6), 64.3% (95% CI, 35.9-80.2), and 65.5% (95% CI, 27.0-83.7), respectively.

Conclusion

The short-term effectiveness of the XBB.1.5 vaccine against symptomatic COVID-19 infection, hospitalization, and receipt of oxygen therapy in South Korea was significant. Long-term vaccine effectiveness warrants evaluation, and these assessments should be conducted regularly.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

International Journal of Infectious Diseases 医学-传染病学

CiteScore

18.90

自引率

2.40%

发文量

1020

审稿时长

30 days

期刊介绍： International Journal of Infectious Diseases (IJID) Publisher: International Society for Infectious Diseases Publication Frequency: Monthly Type: Peer-reviewed, Open Access Scope: Publishes original clinical and laboratory-based research. Reports clinical trials, reviews, and some case reports. Focuses on epidemiology, clinical diagnosis, treatment, and control of infectious diseases. Emphasizes diseases common in under-resourced countries.